<DOC>
	<DOC>NCT02801903</DOC>
	<brief_summary>This is a 21 day, single-center, open-label pharmacokinetic, safety and tolerability study in adolescents with moderate to severe acne vulgaris.</brief_summary>
	<brief_title>Pharmacokinetics of Topical SB204 in Adolescents With Acne Vulgaris</brief_title>
	<detailed_description />
	<mesh_term>Acne Vulgaris</mesh_term>
	<criteria>Otherwise healthy male and female adolescent subjects with moderate to severe acne vulgaris on a 5 point IGA scale At least 20 total inflammatory lesions (papules and pustules), and at least 20 total noninflammatory lesions (open and closed comedones) on the face, chest, back, and shoulders Age 916 years, 11 months inclusive Subjects with methemoglobin level less than 3% at Screening and Baseline by pulse cooximeter Subjects with any other acnelike dermatological conditions such as severe, recalcitrant nodulocystic acne, acne conglobata, acne fulminans, acne secondary to medications or other medical conditions, perioral dermatitis, clinically significant rosacea, or gramnegative folliculitis; Any subject with skin disorders of an acute or chronic nature including psoriasis, eczema, tinea versicolor, etc. Subjects who reside in a dwelling that relies on well water for a primary drinking source Subjects with facial hair (beards, mustaches, etc.), tattoos or other facial markings that would interfere with assessments and study drug application Transgender subjects receiving hormone supplement (male to female or female to male) Subjects with a previous history of methemoglobinemia or taking medications known to be associated with methemoglobinemia Subjects with a known history of HIV, hepatitis, or other bloodborne pathogens Females who are pregnant, planning a pregnancy or breastfeeding Subjects previously treated with NVN1000 Gel / SB204</criteria>
	<gender>All</gender>
	<minimum_age>9 Years</minimum_age>
	<maximum_age>16 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>